S. K. Devana, B. V. Kelley, O. J. McBride, N. Kabir, A. R. Jensen, S. J. Park, C. D. Eliasberg, A. Dar, G. M. Mosich, T. J. Kowalski, B. Péault, F. A. Petrigliano, N. F. SooHoo, Department of Orthopaedic Surgery, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA C. D. Eliasberg, Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, USA T. J. Kowalski, Department of Orthopaedic Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, UK B. Péault, University of Edinburgh, MRC Center for Regenerative Medicine, Edinburgh, UK.
Clin Orthop Relat Res. 2018 Oct;476(10):2091-2100. doi: 10.1097/CORR.0000000000000461.
Achilles tendon rupture is a common injury and the best treatment option remains uncertain between surgical and nonoperative methods. Biologic approaches using multipotent stem cells such as perivascular stem cells pose a possible treatment option, although there is currently a paucity of evidence regarding their clinical therapeutic use.
QUESTIONS/PURPOSES: The purpose of this study was to determine whether injected perivascular stem cells (PSCs) would (1) improve histologic signs of tendon healing (such as percent area of collagen); and (2) improve biomechanical properties (peak load or stiffness) in a rat model of Achilles tendon transection.
Two subtypes of PSCs were derived from human adipose tissue: pericytes (CD146CD34CD45CD31) and adventitial cells (CD146CD34CD45CD31). Thirty-two athymic rats underwent right Achilles transection and were randomized to receive injection with saline (eight tendons), hydrogel (four tendons), pericytes in hydrogel (four tendons), or adventitial cells in hydrogel (eight tendons) 3 days postoperatively with the left serving as an uninjured control. Additionally, a subset of pericytes was labeled with CM-diI to track cell viability and localization. At 3 weeks, the rats were euthanized, and investigators blinded to treatment group allocation evaluated tendon healing by peak load and stiffness using biomechanical testing and percent area of collagen using histologic analysis with picrosirius red staining.
Histologic analysis showed a higher mean percent area collagen for pericytes (30%) and adventitial cells (28%) than hydrogel (21%) or saline (26%). However, a nonparametric statistical analysis yielded no statistical difference. Mechanical testing demonstrated that the pericyte group had a higher peak load than the saline group (41 ± 7 N versus 26 ± 9 N; mean difference 15 N; 95% confidence interval [CI], 4-27 N; p = 0.003) and a higher peak load than the hydrogel group (41 ± 7 N versus 25 ± 3 N; mean difference 16; 95% CI, 8-24 N; p = 0.001). The pericyte group demonstrated higher stiffness than the hydrogel group (36 ± 12 N/mm versus 17 ± 6 N/mm; mean difference 19 N/mm; 95% CI, 5-34 N/mm; p = 0.005).
Our results suggest that injection of PSCs improves mechanical but not the histologic properties of early Achilles tendon healing.
This is a preliminary study that provides more insight into the use of adipose-derived PSCs as a percutaneous therapy in the setting of Achilles tendon rupture. Further experiments to characterize the function of these cells may serve as a pathway to development of minimally invasive intervention aimed at improving nonoperative management while avoiding the complications associated with surgical treatment down the line.
跟腱断裂是一种常见的损伤,手术和非手术方法之间的最佳治疗选择仍不确定。使用多能干细胞(如血管周细胞)的生物学方法提供了一种可能的治疗选择,尽管目前关于其临床治疗应用的证据很少。
问题/目的:本研究旨在确定注射血管周细胞(PSCs)是否会:(1)改善跟腱愈合的组织学迹象(如胶原面积百分比);(2)改善生物力学特性(峰值载荷或刚度)在大鼠跟腱横断模型中。
从人脂肪组织中分离出两种亚型的 PSCs:周细胞(CD146CD34CD45CD31)和外膜细胞(CD146CD34CD45CD31)。32 只无胸腺大鼠行右侧跟腱横断术,术后 3 天随机接受盐水(8 根肌腱)、水凝胶(4 根肌腱)、血管周细胞水凝胶(4 根肌腱)或外膜细胞水凝胶(8 根肌腱)注射,左侧作为未受伤对照。此外,一部分周细胞用 CM-diI 标记以追踪细胞活力和定位。3 周后,大鼠被安乐死,研究人员对治疗组分配进行盲法评估,通过生物力学测试评估肌腱愈合的峰值载荷和刚度,并通过皮尔斯红染色的组织学分析评估胶原面积百分比。
组织学分析显示,周细胞(30%)和外膜细胞(28%)的胶原面积百分比均高于水凝胶(21%)或盐水(26%)。然而,非参数统计分析没有得出统计学差异。力学测试表明,与盐水组相比,周细胞组的峰值载荷更高(41±7 N 与 26±9 N;平均差异 15 N;95%置信区间 [CI],4-27 N;p=0.003),与水凝胶组相比,峰值载荷更高(41±7 N 与 25±3 N;平均差异 16;95%CI,8-24 N;p=0.001)。与水凝胶组相比,周细胞组的刚度更高(36±12 N/mm 与 17±6 N/mm;平均差异 19 N/mm;95%CI,5-34 N/mm;p=0.005)。
我们的结果表明,PSC 的注射可以改善跟腱早期愈合的力学性能,但不能改善组织学特性。
这是一项初步研究,为脂肪来源的 PSCs 作为跟腱断裂的经皮治疗提供了更多的见解。进一步的功能特征研究可以为微创干预的发展提供途径,旨在改善非手术治疗,同时避免手术治疗带来的并发症。